PureTech Announces Annual Results for Year Ended December 31, 2023
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
PureTech Proposes $100 Million Capital Return
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
PureTech to Present at Two Upcoming Investor Conferences
PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
PureTech Year End Update and Outlook for 2024
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
PureTech's LYT-300 Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial
As the year is nearing a close, lawmakers are still chipping away at spending bills and a long to-do list of health policy priorities that could come with some big changes for the biotech industry.